AstraZeneca and Daiichi Sankyo have claimed ... datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after ...

AstraZeneca and Daiichi Sankyo’s antibody-drug ... or negative breast cancer in this and possibly earlier settings.” Dato-DXd has also generated promising results when used alongside Merck ...

Daiichi Sankyo (OTCPK ... its antibody-drug conjugate Dato-DXd marketed with AstraZeneca (NASDAQ:AZN) as a late-line option for certain cases of breast cancer. Issuing a so-called positive opinion ...

AstraZeneca ... metastatic breast cancer, remains under review by the EMA and is based on the TROPION-Breast01 Phase III trial. Datopotamab deruxtecan was discovered by Daiichi Sankyo and is ...

Daiichi Sankyo. “With the results of DESTINY-Breast09 and DESTINY-Gastric04, we now have six breast and two gastric cancer randomized trials that have demonstrated significant survival ...

Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and Datroway. Driven by a growing understanding of breast cancer biology, AstraZeneca is challenging, and redefining, the ...

The blockbuster drug Enhertu from AstraZeneca and Japanese drugmaker Daiichi Sankyo stalled the growth of a common type of breast cancer by more than a year in a large late-stage trial when used ...